| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1040: Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy |
|
Medicine details |
|
| Medicine name | olaparib (Lynparza®) |
| Formulation | 50 mg capsule, 100 mg film-coated tablet, 150 mg film-coated tablet |
| Reference number | 2622 |
| Indication | For the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo) adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/01/2025 |
| NICE guidance | |
| Commercial arrangement | CAA |